<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584844</url>
  </required_header>
  <id_info>
    <org_study_id>A-12775</org_study_id>
    <secondary_id>FY03-24</secondary_id>
    <nct_id>NCT00584844</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine</brief_title>
  <official_title>A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the safety and immunogenicity of a Live Francisella
      tularensis Vaccine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study was designed as a continuation of previously published research and targets subjects
      who were at risk of occupational exposure to F tularensis virus. Based on screening
      examinations; if a subject had a positive baseline titer (&lt;1:20) and gave no history of
      significant exposure to F tularensis or history of tularemia disease, had never received
      tularemia vaccination, and was at risk of exposure to F tularensis they could be enrolled in
      this protocol to receive vaccination. Subjects returned for follow-up exams on Days 1, 2, and
      7; once between Days 12 and 16; and once between Days 28 and 35 post-vaccination. If titers;
      after blood samples on Days 28, 35 and 12 months showed &lt;1:20 the vaccination could be
      repeated at Days 56-84. If the repeat titer remained &lt;1:20, a booster vaccination could be
      administered. Subjects could be boosted 2 times with 1 year. If the titer measured 12 months
      after vaccination (+30 days) was &gt;1:20 and the subject had no lingering AEs, the subjects
      participation was considered complete.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse Event Category Rates for All Vaccinations</measure>
    <time_frame>AEs/SAEs recorded through duration of study; immunogenicity via MA on days 0, 28-35, 56-84, and at 1 year</time_frame>
    <description>AE analysis was conducted for all intent-to-treat subjects regardless of compliance with titer schedule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Protocol Compliant Post-primary Titer Rates</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with less than or greater than titers (&gt; or &lt; 1:20) for compliant post-primary titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Protocol-compliant Post-boost 1 Titer Rates</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with less than or greater than titers (&gt; or &lt; 1:20) who received post-boost 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Protocol-compliant Post-boost 2 Titer</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with less than or greater than titers who received post-boost 2.
Responder = &gt; 1:20 Non-responder = &lt; 1:20</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Tularemia</condition>
  <arm_group>
    <arm_group_label>F tularensis Vaccine (0.0025 mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live F tularensis Vaccine</intervention_name>
    <description>Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (&lt; 1:20).</description>
    <arm_group_label>F tularensis Vaccine (0.0025 mL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old, or if on active military duty, 17 years old

          -  Females of childbearing potential must agree to have a urine pregnancy test
             immediately before vaccination (Exception: documented hysterectomy or &gt; 3 years of
             menopause). The results must be negative. Volunteers must agree not to become pregnant
             for 3 months after receipt of the vaccine.

          -  Subject must be actively enrolled in the SIP

          -  Subjects must be considered at risk for exposure to F. tularensis.

          -  Subjects must have an up-to-date (within 1 year) medical history, physical
             examination, and laboratory tests on their charts and be medically cleared for
             participation by an investigator. Examinations or tests may be repeated within 1 year
             at the discretion of the enrolling physician.

          -  Volunteer must be willing to return for all follow-up visits on days 1, 2, 7, once
             between days 12-16, and once between days 28-35, days 56-84 (if needed), all visits
             for serology, as well as an annual visit while enrolled in protocol.

          -  Volunteer must agree to report any Adverse Event which may or may not be associated
             with administration of the test article for at least 28 days after vaccination. All
             Serious and Unexpected Adverse Events will be reported for the duration of the
             volunteer's participation in the study.

        Exclusion Criteria:

          -  Clinically significant abnormal lab results including evidence of Hepatitis C*,
             Hepatitis B* carrier state, or elevated liver function tests (2X normal values or at
             discretion of PI).

          -  Personal history of an immunodeficiency or current treatment with an oral or
             intravenous immunosuppressive medication.

          -  Confirmed HIV* infection.

          -  Any other medical condition at the discretion of the PI.

          -  Antibiotic therapy for 7 days before vaccination.

          -  Females must not be pregnant or lactating (females must agree to not become pregnant
             for 3 months after vaccination).

          -  Any known allergies to excipients of the vaccine

          -  Administration of another live vaccine within 4 weeks or an inactivated vaccine
             (generally) within 7 days of tularemia vaccination.

          -  Any unresolved adverse event resulting from a previous immunization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USAMRIID Medical Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.S. Army Medical Research Institute of Infectious Diseases</name>
      <address>
        <city>Fort Deterick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <results_first_submitted>December 28, 2016</results_first_submitted>
  <results_first_submitted_qc>June 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Live Vaccine Strain (LVS), Bacterial Infections, Ulceroglandular, Oculoglandular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tularemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment at the Special Immunizations Clinic at USAMRIID is expected to last 5 years and include up to 1,000 subjects who were at risk of occupational exposure to F tularensis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>F Tularensis Vaccine (0.0025 mL)</title>
          <description>Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
Live F tularensis Vaccine: Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (&lt; 1:20).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="405"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>F Tularensis Vaccine (0.0025 mL)</title>
          <description>Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
Live F tularensis Vaccine: Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (&lt; 1:20).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Adverse Event Category Rates for All Vaccinations</title>
        <description>AE analysis was conducted for all intent-to-treat subjects regardless of compliance with titer schedule.</description>
        <time_frame>AEs/SAEs recorded through duration of study; immunogenicity via MA on days 0, 28-35, 56-84, and at 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Males</title>
            <description>All males in study</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>All females in study</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Adverse Event Category Rates for All Vaccinations</title>
          <description>AE analysis was conducted for all intent-to-treat subjects regardless of compliance with titer schedule.</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locale: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship: Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship: Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship: Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship: Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship: Definate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome: Resolved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome: Resolved with sequelae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment required:None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment required: Intervention required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment required: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment required: Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Protocol Compliant Post-primary Titer Rates</title>
        <description>Percentage of subjects with less than or greater than titers (&gt; or &lt; 1:20) for compliant post-primary titers.</description>
        <time_frame>12 months</time_frame>
        <population>As stated in the protocol, only titers taken in compliance with the prescribed schedule were used in the statistical analysis. 454 were compliant and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Percent of Subjects</title>
            <description>Percentage of subjects in specific category</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Protocol Compliant Post-primary Titer Rates</title>
          <description>Percentage of subjects with less than or greater than titers (&gt; or &lt; 1:20) for compliant post-primary titers.</description>
          <population>As stated in the protocol, only titers taken in compliance with the prescribed schedule were used in the statistical analysis. 454 were compliant and analyzed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 28-35: All subjects &lt;1.20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 28-35: All subjects &gt;1.20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 56-84: All subjects &lt;1.20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 56-84: All subjects &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: All subjects &lt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: All subjects &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: &lt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Protocol-compliant Post-boost 1 Titer Rates</title>
        <description>Percentage of subjects with less than or greater than titers (&gt; or &lt; 1:20) who received post-boost 1</description>
        <time_frame>12 months</time_frame>
        <population>As stated in the protocol, only titers taken in compliance with the prescribed schedule were used in the statistical analysis. 19 were compliant and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Percent of Subjects</title>
            <description>Percentage of subjects in specific category</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Protocol-compliant Post-boost 1 Titer Rates</title>
          <description>Percentage of subjects with less than or greater than titers (&gt; or &lt; 1:20) who received post-boost 1</description>
          <population>As stated in the protocol, only titers taken in compliance with the prescribed schedule were used in the statistical analysis. 19 were compliant and analyzed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 28-35: &lt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 28-35: &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 56-84: &lt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 56-84: &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &lt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: &lt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: &gt;1:20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Protocol-compliant Post-boost 2 Titer</title>
        <description>Percentage of subjects with less than or greater than titers who received post-boost 2.
Responder = &gt; 1:20 Non-responder = &lt; 1:20</description>
        <time_frame>12 months</time_frame>
        <population>As stated in the protocol, only titers taken in compliance with the prescribed schedule were used in the statistical analysis. 18 were compliant and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Percent of Subjects</title>
            <description>Percentage of subjects in specific category</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Protocol-compliant Post-boost 2 Titer</title>
          <description>Percentage of subjects with less than or greater than titers who received post-boost 2.
Responder = &gt; 1:20 Non-responder = &lt; 1:20</description>
          <population>As stated in the protocol, only titers taken in compliance with the prescribed schedule were used in the statistical analysis. 18 were compliant and analyzed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 28-35: Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 28-35:Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 56-84: Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 56-84: Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>AE analysis was conducted for all intent-to-treat subjects regardless of compliance with titer schedule. A single AE greater than 1 day duration that changed in severity was tabulated as one AE with only the highest severity coding. AE's were assessed on Days 1, 2, 7, 12-16, 28-35, 56-84 and 12 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mild</title>
          <description>Mild</description>
        </group>
        <group group_id="E2">
          <title>Moderate</title>
          <description>Moderate</description>
        </group>
        <group group_id="E3">
          <title>Severe</title>
          <description>Severe</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.X</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="462"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Spondylolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.X</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="426" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="462"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="82" subjects_affected="79" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="462"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="462"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="462"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="462"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="462"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="370" subjects_affected="355" subjects_at_risk="462"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="104" subjects_affected="104" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="111" subjects_affected="111" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site vesicles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="462"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="462"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Injection site pustule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Animal scratch</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymph node palpable</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="462"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Nodule on extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="43" subjects_affected="42" subjects_at_risk="462"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Spondylolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="86" subjects_affected="86" subjects_at_risk="462"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="462"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="462"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="462"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Goldberg, MD</name_or_title>
      <organization>USAMRIID</organization>
      <phone>301-619-4562</phone>
      <email>mark.goldberg@amedd.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

